Obrixtamig

DRUG5 trials

Sponsors

Boehringer Ingelheim, Technische Universität Dresden

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Extrapulmonary Neuroendocrine Cancer (epNEC)Extrapulmonary Neuroendocrine Carcinoma of Large Cell HistologyExtrapulmonary Neuroendocrine Carcinoma of Small Cell HistologyLarge Cell Neuroendocrine Carcinoma of the LungLarge Cell Neuroendocrine Lung CarcinomaNeuroendocrine NeoplasmsSmall Cell Lung Cancer

Phase 1

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Active, not recruitingNCT05879978

Boehringer IngelheimNeuroendocrine Neoplasms, Small Cell Lung Carcinoma (SCLC)

Start: 2023-06-27End: 2027-03-31Updated: 2026-08-04

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Not yet recruitingNCT07707895

Boehringer IngelheimExtrapulmonary Neuroendocrine Carcinoma of Large Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Large Cell Neuroendocrine Lung Carcinoma +1

Start: 2026-09-29End: 2030-04-26Target: 60Updated: 2026-09-02

Phase 2

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

Not yet recruitingNCT07561645

Technische Universität DresdenLarge Cell Neuroendocrine Carcinoma of the Lung

Start: 2026-09-01End: 2032-04-01Target: 75Updated: 2026-08-26

Phase 3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

RecruitingNCT07472517

Boehringer IngelheimExtensive-stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)

Start: 2026-04-13End: 2029-07-30Target: 670Updated: 2026-09-15

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

RecruitingNCT07544654

Boehringer IngelheimExtrapulmonary Neuroendocrine Cancer (epNEC)

Start: 2026-07-10End: 2031-03-11Target: 390Updated: 2026-09-15